BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31537528)

  • 21. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
    Strati P; Keating MJ; O'Brien SM; Burger J; Ferrajoli A; Jain N; Tambaro FP; Estrov Z; Jorgensen J; Challagundla P; Faderl SH; Wierda WG
    Blood; 2014 Jun; 123(24):3727-32. PubMed ID: 24705492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
    Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
    Hengeveld PJ; van der Klift MY; Kolijn PM; Davi F; Kavelaars FG; de Jonge E; Robrecht S; Assmann JLJC; van der Straten L; Ritgen M; Westerweel PE; Fischer K; Goede V; Hallek M; Levin MD; Langerak AW
    Blood; 2023 Feb; 141(5):519-528. PubMed ID: 36084320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
    Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
    Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
    Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
    Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
    Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
    Duroux-Richard I; Gagez AL; Alaterre E; Letestu R; Khalifa O; Jorgensen C; Leprêtre S; Tchernonog E; Moreaux J; Cartron G; Apparailly F
    Front Immunol; 2022; 13():983771. PubMed ID: 36325355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FCR achieves long-term durable remissions in patients with
    Chai-Adisaksopha C; Brown JR
    Blood; 2017 Nov; 130(21):2278-2282. PubMed ID: 29025740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
    Herling CD; Cymbalista F; Groß-Ophoff-Müller C; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Busch R; Porcher R; Cazin B; Dreyfus B; Ibach S; Leprêtre S; Fischer K; Kaiser F; Eichhorst B; Wentner CM; Hoechstetter MA; Döhner H; Leblond V; Kneba M; Letestu R; Böttcher S; Stilgenbauer S; Hallek M; Levy V
    Leukemia; 2020 Aug; 34(8):2038-2050. PubMed ID: 32071431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
    Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
    Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
    Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Suzumiya J; Takizawa J
    Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
    Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.